ClinicalTrials.gg
RecruitingNCT06643962Updated Nov 12, 2024

Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy

An interventional study of Venetoclax and Idarubincin in Leukemia, Leukemia, Myeloid and Leukemia, Myeloid, Acute, sponsored by Affiliated Hospital of Nantong University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-11-12.

Primary conditionLeukemia, Myeloid, AcuteRegistry: LeukemiaReclassifiedWhy we changed it
Registry
Leukemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myeloid, Acute
Why
  1. The study's listed conditions name Leukemia, Myeloid, Acute, a narrower term within Leukemia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Affiliated Hospital of Nantong University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
83
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 203 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 145 under way, 22 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.

Planned enrollment
86th of 203
83 · median 58
Started
2024
with 34 others
No phase
16 of 203
12 open now
Primary completion
2025-12
later than 25 of 144 live
Registered
150th of 203
by date

Among the 203 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 86th largest by planned enrollment, is one of 35 that started in 2024, is one of 16 with no phase, reaches primary completion later than 25 of the 144 other live ones, and was the 150th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

116 of the 203 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

111 more — sign in →

By country, each count listing its studies:

All 116 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 203 studies testing venetoclax in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This single-center prospective cohort study aims to evaluate the efficacy and safety of Intensifying treatment with Venetoclax along with intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia (AML) except acute promyelocytic leukemia (non-APL) and exhibiting lower early peripheral blast clearance rate (EPBCR) after standard Intensive Induction therapy (3+7 regimen).

Read the detailed description

This is a single-center, prospective cohort study for the intensifying treatment with venetoclax on the standard 3+7 regimen in newly diagnosed AML (non-APL) participants who have lower EPBCR based on ≦1.5log on day 4 of the 3+7 regimen.

The key eligible criteria are newly diagnosed and treatment-naïve AML (non-APL) according to the WHO 2022 criteria. Participants are between 18 and 70 years old and fit for intensive chemotherapy. A leukemia-associated immunophenotype (LAIP) defined by multiparameter flow cytometry (MFC) according to the 2022 ELN recommendation (2022 ELN) is necessary for enrollment in this trial.

All eligible participants receive the 3+7 regimen. Pretreatment with hydroxyurea is permitted to manage leukocytosis.

LAIP+ cells are enumerated on EDTA-anticoagulated peripheral blood collected before chemotherapy on days 1 and 4 of the first induction cycle (each cycle is 28 days). At least 100 circulating LAIP+ cells per microliter on day 1 are required as inclusion criteria to ensure optimal sensitivity. The EPBCR is calculated on day 4 of the first induction regimen as a ratio converted to a logarithmic scale between the absolute peripheral blood LAIP+ cell count on day 1 (baseline) and day 4. A cut-off of 1.5 log is decisional to assign participants to treatment modalities. Participants with EPBCR>1.5 log (EPBCRhigh) complete the 3+7 regimen and are managed according to standard clinical practice. Participants with EPBCR≦1.5 log (EPBCRlow) receive intensified treatment with venetoclax orally along with the standard 3+7 regimen on days 5-14. A venetoclax dose ramp-up schedule is required in the first induction therapy.

After two cycles of induction therapy, participants who fail to achieve composite complete remission (CR/CRi, CRc) may receive an alternative regimen per their physicians' decision.

After CR/CRi is achieved, participants proceed with consolidation therapy or allo-HSCT based on their 2022 ELN risk categories. Participants with favorable risk should go through four cycles (each cycle is 28 days) of consolidation therapy, those with adverse risk should go through allogeneic hematopoietic stem cell transplantation (allo-HSCT) after two cycles of consolidation therapy, and those with intermediate risk can receive allo-HSCT after two cycles of consolidation therapy if suitable donors are available or continue with four cycles of consolidation therapy. Participants receive four cycles of consolidation regimen of intermediate-dose cytarabine for age >60 years old or high-dose cytarabine for age >60 years old. The consolidation therapy will be combined with venetoclax in the EPBCRlow cohort and not in the EPBCRhigh cohort.

After consolidation, participants will receive maintenance therapy per their physicians' decision and be observed.

03

Conditions studied

  • Leukemia
  • Leukemia, Myeloid
  • Leukemia, Myeloid, Acute

Browse trials for

Keywords

  • acute myeloid leukemia
  • venetoclax
  • intensive chemotherapy
  • early peripheral blast clearance
  • newly diagnosed
04

In context

Leukemia, Myeloid, Acute Reclassified

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

This study's planned enrollment of 83 is above the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

Affiliated Hospital of Nantong University is the lead sponsor of 97 studies on the registry; 57 are open to participants now.

Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed AML, except for the APL subtype, according to the 2022 World Health Organization classification (WHO 2022 criteria)
  • Age ≥18 years and ≤70 years
  • Eligible for intensive chemotherapy
  • No prior chemotherapy for AML except hydroxyurea for up to 14 days during the diagnostic screening phase for the control of peripheral leukemic blasts in patients with leukocytosis (e.g., white blood cell [WBC] counts>25x10\^9/L)
  • (ECOG) performance status≤2
  • Adequate renal function is defined as:

    • Serum creatinine≤2.0× (ULN)
    • (CrCl)>30 mL/min calculated by the Cockcroft-Gault equation.
  • Adequate hepatic and heart function is defined as:

    • Serum total ≤1.5×ULN unless considered due to Gilbert's disease, or leukemic involvement
    • (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP)≤2.5×ULN, unless considered due to leukemic involvement
    • Myocardial enzyme\<2.0×ULN
    • is within the normal range by measure of echocardiogram (ECHO)
  • Signed a written form (ICF)
  • Female participants who are of non- (i.e., by history of no menses for ≥1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Female participants of must have a negative serum pregnancy test upon study entry

Exclusion criteria

Exclusion Criteria:

  • AML with BCR-ABL1 or myeloid blast crisis of CML
  • Participants who have received prior treatment for AML with chemotherapy, hypomethylating agents, or venetoclax
  • Participants who are ineligible for intensive induction chemotherapy:

    • ≧71 years old OR
    • ≧18 to 70 years old and fulfill at least one criterion associated with lack of fitness for intensive induction chemotherapy:

      • PS of 2-3
      • Cardiac history of CHF requiring treatment or ≦50% or chronic stable angina
      • Diffusing capacity of the lungs for carbon monoxide (DLCO)≦65% or the (FEVI) ≦65%
  • Participants with a prior history of MDS, MPN, or MDS/MPN
  • Participants with other concurrent malignant tumors on treatment, except for:

    • treated with curative intent and with no known active disease present for ≧3 years
    • Adequately treated non-melanoma skin cancer or lentigo maligna without current evidence of disease
    • Adequately treated carcinoma in situ without current evidence of disease
    • Localized prostate cancer with a Gleason score of 6 or less
  • Pregnant or lactating women
  • Active heart disease is defined as any one of the following:

    • Uncontrolled or symptomatic angina pectoris
    • A myocardial infarction six months before enrolled
    • Arrhythmia needs medication or with severe clinical symptoms
    • Uncontrolled or symptomatic congestive heart failure (New York Hear Association [] classification> grade 2)
  • Participants with an active, uncontrolled, systemic fungal, bacterial, or viral infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment
  • Participants with an active viral infection caused by , , or virus that cannot be controlled by treatment
  • Participants with evidence of central nervous system leukemia before the study treatment
  • Participants with epilepsy which needs drug treatment, dementia, or other abnormal mental states that prevent understanding or following the protocol
  • Conditions that restrict the intake or absorption of orally administered drugs
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
83 participants (estimated)

Study arms

  • Experimental
    Assigned interventions

    Participants with EPBCR\>1.5 log (EPBCRhigh) complete the 3+7 regimen and are managed according to standard clinical practice. Participants with EPBCR≦1.5 log (EPBCRlow) receive intensified treatment with venetoclax orally along with the standard 3+7 regimen on days 5-14. A venetoclax dose ramp-up schedule is required in the first induction therapy.

    Drug: Venetoclax · Drug: Idarubincin · Drug: Cytarabine

Interventions

  • Venetoclax in the EPBCRlow cohort will be added to the ongoing 3+7 regimen. In the first induction cycle: venetoclax needs to be ramped up: 100 mg on day 5, 200mg on day 6, and 400mg on days 7-14, orally once daily. In the second induction (if required), venetoclax 400mg will be administered orally once daily on days 5-14 without a dose ramp-up schedule. Venetoclax in the EPBCRlow cohort during consolidation therapy: 400mg on days 1-7, orally once daily, along with the consolidation chemotherapy.

    Also known as: Bcl-2 inhibitors

  • DrugIdarubicinStudies of IdarubicinIdarubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Idarubicin (IDA): 10mg/m\^2/d (age \<60 years old) or 6mg/m\^2/d on days 1-3, intravenously (IV).

    Also known as: IDA

  • During induction therapy: 100mg/m2/d on days 1-7, IV. During consolidation therapy: intermediate-dose cytarabine for age \>55 years old: 1.0g/m\^2 q12h on days 1-3, high-dose cytarabine for age ≦55 years old: 2g/m2 q12h on days 1-3.

    Also known as: Ara-C

07

What researchers measure

Primary outcomes

  1. CRc rate after one cycle of induction therapy

    The proportion of participants achieving CR/CRi by the initiation of next cycle of therapy (each cycle is 28 days).

    Time frame: Up to one month

Secondary outcomes

  1. CRc rate after two cycle of induction therapy

    The cumulative proportion of participants achieving CR/CRi after two cycles of induction therapy and before starting the next cycle of therapy.

    Time frame: Up to 2 months

  2. CRMRD-Rate

    The cumulative proportion of participants achieving CR/CRi without measurable residual disease after two cycles of induction therapy and before starting the next cycle of therapy.

    Time frame: Up to 2 months

  3. Event-free survival (EFS)

    The time from enrollment to treatment failure is defined as failure to achieve CR, CRi, or PR after two cycles of induction therapy, death from any cause, or relapse after achieving CR/CRi, whichever occurs first. If no specified events occur at the date of the last disease assessment, participants will be censored.

    Time frame: Up to 12 months

  4. Relapse free survival (RFS)

    From the date of achieving CR/CRi until the date of documented relapse or death due to any cause or the last follow-up day. If no specified events occur at the date of the last disease assessment, participants will be censored.

    Time frame: Up to 24 months

  5. Overall survival Overall survival (OS)

    The time from enrollment to death due to any cause. If death does not occur at the date of the last disease assessment, participants will be censored.

    Time frame: Up to 24 months

Other outcomes

  1. Baseline genomics

    Genomics at baseline will be assessed at diagnosis using the Next-generation DNA sequencing.

    Time frame: Up to one month

  2. Baseline transcriptomics

    Transcriptomics at baseline will be assessed at diagnosis using the Next-generation RNA sequencing.

    Time frame: Up to one month

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2025, 14 months after the start.

Of 132 non-industry interventional studies with no phase under Leukemia, Myeloid, Acute, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 128. This study's planned 14 months is below that.

Counting every sponsor, half of 139 studies reached it within 47 months; a quarter within 25 and three quarters within 123.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2024
First posted
Oct 16, 2024
StartActual
Oct 31, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Oct 31, 2027
Last update
Nov 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06643962
Lead sponsor
Affiliated Hospital of Nantong University
Responsible party
Sponsor
First posted
Oct 16, 2024
Start date
Oct 31, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Nov 12, 2024

Study contacts

Yingxin Sun, Dr
Contact
syx20194132088@163.com
+86-13646249970

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion